ABUS - Arbutus Biopharma Corp

QQQ $ 440.32 $ 0.07 (0.02 %)

DIA $ 388.70 $ 0.29 (0.07 %)

SPY $ 517.26 $ 0.57 (0.11 %)

TLT $ 90.79 $ 0.55 (0.61 %)

GLD $ 214.23 $ -0.99 (-0.46 %)

Previous Close

$ 2.84

Open

$ 2.84

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.80 - $ 2.84

52 Week Range

$ 1.69 - $ 3.29

Volume

619,155

Average Volume

Market Cap

535.96M

Beta (5Y Monthly)

$ 1.11

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	03-05-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-02-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	03-03-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	03-04-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-07-2020	06-30-2020	10-Q
17	05-11-2020	03-31-2020	10-Q
18	03-05-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-05-2019	06-30-2019	10-Q
21	05-06-2019	03-31-2019	10-Q
22	03-07-2019	12-31-2018	10-K
23	11-07-2018	09-30-2018	10-Q
24	08-03-2018	06-30-2018	10-Q
25	05-04-2018	03-31-2018	10-Q
26	03-16-2018	12-31-2017	10-K
27	11-02-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	03-22-2017	12-31-2016	10-K
31	11-03-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-04-2016	03-31-2016	10-Q
34	03-09-2016	12-31-2015	10-K
35	11-05-2015	09-30-2015	10-Q
36	08-07-2015	06-30-2015	10-Q
37	05-06-2015	03-31-2015	10-Q
38	03-13-2015	12-31-2014	10-K
39	11-07-2014	09-30-2014	10-Q
40	08-14-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Chardan Capital Reiterates Buy on Arbutus ...
05/03/2024 13:21:22

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

Arbutus Biopharma Q1 EPS $(0.10) Beats $(0...
05/02/2024 11:31:35

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0...

arbutus-vs-moderna-patent-dispute-over-covid-19-vaccine-gets-response-from-judge

Arbutus Vs. Moderna Patent Dispute Over Co...
04/04/2024 18:32:00

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

moderna-shares-slip-over-covid-vaccine-patent-dispute-but-chart-signals-potential-rebound-ahead

Moderna Shares Slip Over Covid Vaccine Pat...
04/04/2024 13:34:25

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or avera...

JMP Securities Reiterates Market Outperfor...
04/04/2024 12:49:09

JMP Securities analyst Roy Buchanan reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and maintains $4 pri...

Arbutus Biopharma Announces Claim Construc...
04/04/2024 12:42:17

The following summarizes the Court's Opinion:Composition of Total Lipid (‘069)The Court agreed with Plaintiffs' positio...

arbutus-stock-soars-20-as-it-heads-to-trial-with-moderna-in-covid-vaccine-patent-claim

Arbutus Stock Soars 20% As It Heads To Tri...
04/03/2024 19:37:15

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against M...

Watching Arbutus Biopharma; Traders Circul...
04/03/2024 16:22:12

Arbutus and Genevant vs Moderna Claim Construction Order.pdf | DocDroid

Chardan Capital Reiterates Buy on Arbutus ...
03/01/2024 12:48:45

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

HC Wainwright & Co. Maintains Buy on Arbut...
03/01/2024 12:22:57

HC Wainwright & Co. analyst Ed Arce maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and lowers the price target fro...

Arbutus Biopharma's 2023 End Cash And Inve...
02/29/2024 12:40:10

Arbutus Biopharma Q4 EPS $(0.12), Inline, ...
02/29/2024 12:36:53

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This i...

Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

Watching Arbutus Biopharma; Hearing Jeffer...
02/08/2024 18:13:15

Barinthus Bio Said Initial Data From The C...
11/09/2023 21:27:38

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained we...

Arbutus Biopharma Q3 2023 EPS $(0.12) Miss...
11/07/2023 12:34:44

Arbutus Says Announces Workforce Reduction...
11/07/2023 12:32:59

Arbutus CEO William Collier To Retire At T...
11/07/2023 12:21:00

Arbutus CEO William Collier To Retire Dec....
11/07/2023 12:18:28

Earnings Scheduled For November 7, 2023
11/07/2023 11:34:30

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.